Literature DB >> 20807885

Cells expressing FLT3/ITD mutations exhibit elevated repair errors generated through alternative NHEJ pathways: implications for genomic instability and therapy.

Jinshui Fan1, Li Li, Donald Small, Feyruz Rassool.   

Abstract

The internal tandem duplication (ITD) mutations of the FMS-like tyrosine kinase-3 (FLT3) receptor found in acute myeloid leukemia patients are associated with poor prognosis. Although DNA double-strand breaks (DSBs) are mainly repaired by the DNA-PK-dependent nonhomologous end-joining (NHEJ) pathway in normal mammalian cells, an alternative and less well-defined NHEJ pathway, characterized by microhomology at the repair junctions, play a role in the generation of deletions and translocations leading to cancer progression. Here we report that in FLT3/ITD-expressing cell lines and bone marrow mononuclear cells from FLT3/ITD knock-in mice, end-joining of DSBs occurs at microhomologous sequences resulting in a high frequency of DNA deletions. Strikingly, levels of Ku proteins, key components of the main NHEJ pathway, are decreased in FLT3/ITD(+) cell lines and murine FLT3/ITD bone marrow mononuclear cells. Concomitantly, levels of DNA ligase IIIα, a component of ALT NHEJ, are increased in FLT3/ITD-expressing cells. Cells treated with a FLT3 inhibitor demonstrate decreased DNA ligase IIIα and a reduction in DNA deletions, suggesting that FLT3 signaling regulates the pathways by which DSBs are repaired. Thus, therapy to inhibit FLT3/ITD signaling and/or DNA ligase IIIα may lead to repair that reduces repair errors and genomic instability.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20807885      PMCID: PMC3012544          DOI: 10.1182/blood-2010-03-272591

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  41 in total

1.  Unrepaired DNA breaks in p53-deficient cells lead to oncogenic gene amplification subsequent to translocations.

Authors:  Chengming Zhu; Kevin D Mills; David O Ferguson; Charles Lee; John Manis; James Fleming; Yijie Gao; Cynthia C Morton; Frederick W Alt
Journal:  Cell       Date:  2002-06-28       Impact factor: 41.582

2.  A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo.

Authors:  Mark Levis; Jeffrey Allebach; Kam-Fai Tse; Rui Zheng; Brenda R Baldwin; B Douglas Smith; Susan Jones-Bolin; Bruce Ruggeri; Craig Dionne; Donald Small
Journal:  Blood       Date:  2002-06-01       Impact factor: 22.113

3.  Myeloid leukemias have increased activity of the nonhomologous end-joining pathway and concomitant DNA misrepair that is dependent on the Ku70/86 heterodimer.

Authors:  Terry J Gaymes; Ghulam J Mufti; Feyruz V Rassool
Journal:  Cancer Res       Date:  2002-05-15       Impact factor: 12.701

Review 4.  Role of FLT3 in leukemia.

Authors:  D Gary Gilliland; James D Griffin
Journal:  Curr Opin Hematol       Date:  2002-07       Impact factor: 3.284

5.  Internal tandem duplication of the flt3 gene found in acute myeloid leukemia.

Authors:  M Nakao; S Yokota; T Iwai; H Kaneko; S Horiike; K Kashima; Y Sonoda; T Fujimoto; S Misawa
Journal:  Leukemia       Date:  1996-12       Impact factor: 11.528

6.  DNA repair protein Ku80 suppresses chromosomal aberrations and malignant transformation.

Authors:  M J Difilippantonio; J Zhu; H T Chen; E Meffre; M C Nussenzweig; E E Max; T Ried; A Nussenzweig
Journal:  Nature       Date:  2000-03-30       Impact factor: 49.962

7.  Reduced DNA double strand breaks in chlorambucil resistant cells are related to high DNA-PKcs activity and low oxidative stress.

Authors:  Istvan Boldogh; Gargi Roy; Myung Soog Lee; Attila Bacsi; Tapas K Hazra; Kishor K Bhakat; Gokul C Das; Sankar Mitra
Journal:  Toxicology       Date:  2003-11-15       Impact factor: 4.221

8.  Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia.

Authors:  B Douglas Smith; Mark Levis; Miloslav Beran; Francis Giles; Hagop Kantarjian; Karin Berg; Kathleen M Murphy; Tianna Dauses; Jeffrey Allebach; Donald Small
Journal:  Blood       Date:  2004-01-15       Impact factor: 22.113

Review 9.  Targeted therapies in myeloid leukemia.

Authors:  Alison M John; N Shaun B Thomas; Ghulam J Mufti; Rose Ann Padua
Journal:  Semin Cancer Biol       Date:  2004-02       Impact factor: 15.707

Review 10.  The role of FLT3 in haematopoietic malignancies.

Authors:  Derek L Stirewalt; Jerald P Radich
Journal:  Nat Rev Cancer       Date:  2003-09       Impact factor: 60.716

View more
  44 in total

1.  Targeting abnormal DNA double-strand break repair in tyrosine kinase inhibitor-resistant chronic myeloid leukemias.

Authors:  L A Tobin; C Robert; A P Rapoport; I Gojo; M R Baer; A E Tomkinson; F V Rassool
Journal:  Oncogene       Date:  2012-05-28       Impact factor: 9.867

Review 2.  On the sequence-directed nature of human gene mutation: the role of genomic architecture and the local DNA sequence environment in mediating gene mutations underlying human inherited disease.

Authors:  David N Cooper; Albino Bacolla; Claude Férec; Karen M Vasquez; Hildegard Kehrer-Sawatzki; Jian-Min Chen
Journal:  Hum Mutat       Date:  2011-09-02       Impact factor: 4.878

3.  Defective nonhomologous end joining blocks B-cell development in FLT3/ITD mice.

Authors:  Li Li; Li Zhang; Jinshui Fan; Kathleen Greenberg; Stephen Desiderio; Feyruz V Rassool; Donald Small
Journal:  Blood       Date:  2011-01-12       Impact factor: 22.113

Review 4.  Obesity and cancer: A mechanistic overview of metabolic changes in obesity that impact genetic instability.

Authors:  Pallavi Kompella; Karen M Vasquez
Journal:  Mol Carcinog       Date:  2019-06-05       Impact factor: 4.784

Review 5.  Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights.

Authors:  Prithviraj Bose; Yun Dai; Steven Grant
Journal:  Pharmacol Ther       Date:  2014-04-24       Impact factor: 12.310

6.  c-MYC Generates Repair Errors via Increased Transcription of Alternative-NHEJ Factors, LIG3 and PARP1, in Tyrosine Kinase-Activated Leukemias.

Authors:  Nidal Muvarak; Shannon Kelley; Carine Robert; Maria R Baer; Danilo Perrotti; Carlo Gambacorti-Passerini; Curt Civin; Kara Scheibner; Feyruz V Rassool
Journal:  Mol Cancer Res       Date:  2015-03-31       Impact factor: 5.852

Review 7.  Genomic instability is a principle pathologic feature of FLT3 ITD kinase activity in acute myeloid leukemia leading to clonal evolution and disease progression.

Authors:  Melanie T Rebechi; Keith W Pratz
Journal:  Leuk Lymphoma       Date:  2017-02-06

8.  Targeting abnormal DNA repair in therapy-resistant breast cancers.

Authors:  Lisa A Tobin; Carine Robert; Pratik Nagaria; Saranya Chumsri; William Twaddell; Olga B Ioffe; George E Greco; Angela H Brodie; Alan E Tomkinson; Feyruz V Rassool
Journal:  Mol Cancer Res       Date:  2011-11-23       Impact factor: 5.852

Review 9.  Interplay between DNA Polymerases and DNA Ligases: Influence on Substrate Channeling and the Fidelity of DNA Ligation.

Authors:  Melike Çağlayan
Journal:  J Mol Biol       Date:  2019-04-26       Impact factor: 5.469

10.  The novel Chk1 inhibitor MK-8776 sensitizes human leukemia cells to HDAC inhibitors by targeting the intra-S checkpoint and DNA replication and repair.

Authors:  Yun Dai; Shuang Chen; Maciej Kmieciak; Liang Zhou; Hui Lin; Xin-Yan Pei; Steven Grant
Journal:  Mol Cancer Ther       Date:  2013-03-27       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.